AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
All Articles
Resistance to KRAS Inhibitors Is Multilayered, and Lineage Plasticity Deserves More Attention
By Konstantin Dragnev, MD
Resistance to KRAS inhibitors should be understood as three distinct categories, primary/intrinsic, adaptive/non-genetic, and acquired/genetic, each with different mechanisms and different implications for how to sequence or combine therapy.
Resistance to KRAS Inhibitors Is Multilayered, and Lineage Plasticity Deserves More Attention
By Konstantin Dragnev, MD
Resistance to KRAS inhibitors should be understood as three distinct categories, primary/intrinsic, adaptive/non-genetic, and acquired/genetic, each with different mechanisms and different implications for how to sequence or combine therapy.
Resistance to KRAS Inhibitors Is Multilayered, and Lineage Plasticity Deserves More Attention
By Konstantin Dragnev, MD
Resistance to KRAS inhibitors should be understood as three distinct categories, primary/intrinsic, adaptive/non-genetic, and acquired/genetic, each with different mechanisms and different implications for how to sequence or combine therapy.
Castleman Disease: Redefining the Spectrum Between "One Lymph Node" and "Many"
By Joshua Brandstadter, MD, PhD, MSc
Castleman disease is not one disease but a polyclonal lymphoproliferative disorder spanning a spectrum from single-lymph-node (unicentric) to widespread (multicentric) involvement, with an emerging "oligocentric" category recognized in between.
Castleman Disease: Redefining the Spectrum Between "One Lymph Node" and "Many"
By Joshua Brandstadter, MD, PhD, MSc
Castleman disease is not one disease but a polyclonal lymphoproliferative disorder spanning a spectrum from single-lymph-node (unicentric) to widespread (multicentric) involvement, with an emerging "oligocentric" category recognized in between.
Castleman Disease: Redefining the Spectrum Between "One Lymph Node" and "Many"
By Joshua Brandstadter, MD, PhD, MSc
Castleman disease is not one disease but a polyclonal lymphoproliferative disorder spanning a spectrum from single-lymph-node (unicentric) to widespread (multicentric) involvement, with an emerging "oligocentric" category recognized in between.
EGFR Resistance Is Genuinely Heterogeneous, and That Should Change How We Study New Drugs
By Joshua Sabari, MD
Resistance to third-generation EGFR inhibitors is far more heterogeneous than the resistance patterns seen after earlier-generation drugs, and in 40-50% of patients, no single resistance mechanism can even be identified.
EGFR Resistance Is Genuinely Heterogeneous, and That Should Change How We Study New Drugs
By Joshua Sabari, MD
Resistance to third-generation EGFR inhibitors is far more heterogeneous than the resistance patterns seen after earlier-generation drugs, and in 40-50% of patients, no single resistance mechanism can even be identified.
EGFR Resistance Is Genuinely Heterogeneous, and That Should Change How We Study New Drugs
By Joshua Sabari, MD
Resistance to third-generation EGFR inhibitors is far more heterogeneous than the resistance patterns seen after earlier-generation drugs, and in 40-50% of patients, no single resistance mechanism can even be identified.
HIF-2 Alpha Inhibition in Kidney Cancer: From Adjuvant Belzutifan to the Post-Immunotherapy Setting
By Haris Zahoor, MD
HIF-2 alpha inhibition, first validated in metastatic clear cell renal cell carcinoma (RCC) with belzutifan, is now extending into new treatment settings.
HIF-2 Alpha Inhibition in Kidney Cancer: From Adjuvant Belzutifan to the Post-Immunotherapy Setting
By Haris Zahoor, MD
HIF-2 alpha inhibition, first validated in metastatic clear cell renal cell carcinoma (RCC) with belzutifan, is now extending into new treatment settings.
HIF-2 Alpha Inhibition in Kidney Cancer: From Adjuvant Belzutifan to the Post-Immunotherapy Setting
By Haris Zahoor, MD
HIF-2 alpha inhibition, first validated in metastatic clear cell renal cell carcinoma (RCC) with belzutifan, is now extending into new treatment settings.
Daraxonrasib and the RAS(ON) Revolution in Pancreatic Cancer Treatment
By Andrew H. Ko, MD
A new oral RAS(ON) inhibitor, daraxonrasib, nearly doubled overall survival compared with chemotherapy in patients with previously treated metastatic pancreatic cancer in the Phase 3 RASolute 302 trial.
Daraxonrasib and the RAS(ON) Revolution in Pancreatic Cancer Treatment
By Andrew H. Ko, MD
A new oral RAS(ON) inhibitor, daraxonrasib, nearly doubled overall survival compared with chemotherapy in patients with previously treated metastatic pancreatic cancer in the Phase 3 RASolute 302 trial.
Daraxonrasib and the RAS(ON) Revolution in Pancreatic Cancer Treatment
By Andrew H. Ko, MD
A new oral RAS(ON) inhibitor, daraxonrasib, nearly doubled overall survival compared with chemotherapy in patients with previously treated metastatic pancreatic cancer in the Phase 3 RASolute 302 trial.
How to Treat Mantle Cell Lymphoma in 2026
By Yucai Wang, MD, PhD
Frontline treatment for mantle cell lymphoma (MCL) is no longer a simple, one-size-fits-all algorithm split by transplant eligibility
How to Treat Mantle Cell Lymphoma in 2026
By Yucai Wang, MD, PhD
Frontline treatment for mantle cell lymphoma (MCL) is no longer a simple, one-size-fits-all algorithm split by transplant eligibility
How to Treat Mantle Cell Lymphoma in 2026
By Yucai Wang, MD, PhD
Frontline treatment for mantle cell lymphoma (MCL) is no longer a simple, one-size-fits-all algorithm split by transplant eligibility
The First Positive Phase 3 Trial Ever in Dedifferentiated Liposarcoma Changes a Difficult Conversation
By David Savage, MD
Dedifferentiated liposarcoma has had no positive phase 3 trial in its history, and existing chemotherapy options rarely delay progression beyond a few months.
The First Positive Phase 3 Trial Ever in Dedifferentiated Liposarcoma Changes a Difficult Conversation
By David Savage, MD
Dedifferentiated liposarcoma has had no positive phase 3 trial in its history, and existing chemotherapy options rarely delay progression beyond a few months.
The First Positive Phase 3 Trial Ever in Dedifferentiated Liposarcoma Changes a Difficult Conversation
By David Savage, MD
Dedifferentiated liposarcoma has had no positive phase 3 trial in its history, and existing chemotherapy options rarely delay progression beyond a few months.
Will Multispecific CAR T-Cell Therapy Replace Single-Target CD19 Treatment in Lymphoma?
By Saurabh Dahiya, MD, FACP
CD19-directed CAR T-cell therapy has transformed care for B-cell lymphomas, but most patients still relapse, often due to loss of the CD19 target.
Will Multispecific CAR T-Cell Therapy Replace Single-Target CD19 Treatment in Lymphoma?
By Saurabh Dahiya, MD, FACP
CD19-directed CAR T-cell therapy has transformed care for B-cell lymphomas, but most patients still relapse, often due to loss of the CD19 target.
Will Multispecific CAR T-Cell Therapy Replace Single-Target CD19 Treatment in Lymphoma?
By Saurabh Dahiya, MD, FACP
CD19-directed CAR T-cell therapy has transformed care for B-cell lymphomas, but most patients still relapse, often due to loss of the CD19 target.
KSHV-Associated Multicentric Castleman Disease: A Distinct Diagnosis With Distinct Treatment Considerations
By Kathryn Lurain, MD, MPH
KSHV/HHV8-associated multicentric Castleman disease (MCD) shares clinical features with idiopathic multicentric Castleman disease but has a distinct viral cause
KSHV-Associated Multicentric Castleman Disease: A Distinct Diagnosis With Distinct Treatment Considerations
By Kathryn Lurain, MD, MPH
KSHV/HHV8-associated multicentric Castleman disease (MCD) shares clinical features with idiopathic multicentric Castleman disease but has a distinct viral cause
KSHV-Associated Multicentric Castleman Disease: A Distinct Diagnosis With Distinct Treatment Considerations
By Kathryn Lurain, MD, MPH
KSHV/HHV8-associated multicentric Castleman disease (MCD) shares clinical features with idiopathic multicentric Castleman disease but has a distinct viral cause
Kidney Cancer Treatment Keeps Diversifying: Dual Immunotherapy, HIF-2α Inhibition, and the Search for a TKI-Free Interval
By Randy F. Sweis, MD
Frontline treatment of advanced renal cell carcinoma (RCC) now centers on a choice between dual immunotherapy and immunotherapy-TKI combinations, each with different tradeoffs in response rate versus durable remission.
Kidney Cancer Treatment Keeps Diversifying: Dual Immunotherapy, HIF-2α Inhibition, and the Search for a TKI-Free Interval
By Randy F. Sweis, MD
Frontline treatment of advanced renal cell carcinoma (RCC) now centers on a choice between dual immunotherapy and immunotherapy-TKI combinations, each with different tradeoffs in response rate versus durable remission.
Kidney Cancer Treatment Keeps Diversifying: Dual Immunotherapy, HIF-2α Inhibition, and the Search for a TKI-Free Interval
By Randy F. Sweis, MD
Frontline treatment of advanced renal cell carcinoma (RCC) now centers on a choice between dual immunotherapy and immunotherapy-TKI combinations, each with different tradeoffs in response rate versus durable remission.